STANDARD_NAME	WANG_RECURRENT_LIVER_CANCER_UP
SYSTEMATIC_NAME	M10922
COLLECTION	C2:CGP
MSIGDB_URL	https://www.gsea-msigdb.org/gsea/msigdb/human/geneset/WANG_RECURRENT_LIVER_CANCER_UP
NAMESPACE	HUMAN_GENE_SYMBOL
DESCRIPTION_BRIEF	Genes up-regulated in samples from patients with recurrent hepatocellular carcinoma (HCC).
DESCRIPTION_FULL	PURPOSE: To improve the clinical management of human hepatocellular carcinoma (HCC) by accurate identification, at diagnosis, of patients at risk of recurrence after primary treatment for HCC. EXPERIMENTAL DESIGN: Two clinicopathologic variables available at diagnosis, vascular invasion and cirrhosis, together with molecular profiling using Affymetrix human HG-U133A and HG-U133B oligonucleotide probe arrays, were used to identify recurrent HCC disease. RESULTS: HCC patients presented clinically at diagnosis with vascular invasion and cirrhosis showed a high rate (78-83%) of developing recurrent disease within 6 to 35 months. In comparison, most of the HCC patients (80-100%) without vascular invasion and cirrhosis remained disease-free. However, the risk of recurrent disease for HCC patients with either vascular invasion or cirrhosis could not be accurately ascertained. Using a pool of 23 HCC patients with either vascular invasion or cirrhosis as training set, a 57-gene signature was derived and could predict recurrent disease at diagnosis, with 84% (sensitivity 86%, specificity 82%) accuracy, for a totally independent test set of 25 HCC patients with either vascular invasion or cirrhosis. On further analysis, the disease-free rate was significantly different between patients that were predicted to recur or not to recur in the test group (P = 0.002). CONCLUSION: We have presented data to show that by incorporating the status of vascular invasion and cirrhosis available at diagnosis for patients with HCC after partial curative hepatectomy and a novel 57-member gene signature, we could accurately stratify HCC patients with different risks of recurrence.
PMID	17975138
GEOID	E-MEXP-84,E-TABM-292
AUTHORS	Wang SM,Ooi LL,Hui KM
CONTRIBUTOR	Yujin Hoshida
CONTRIBUTOR_ORG	Broad Institute
EXACT_SOURCE	Fig.3A
FILTERED_BY_SIMILARITY	
EXTERNAL_NAMES_FOR_SIMILAR_TERMS	
EXTERNAL_DETAILS_URL	
SOURCE_MEMBERS	CETN2,CUL4B,DNAJC10,FAM33A,FLJ11016,KCNK1,LOC159090,MPHOSPH9,PARD3,PTPN11,R3HDM,RACGAP1,RPL10A,SH3GLB2,SMURF2,SSR3,SYNGR2,USH1C,ZBTB38,ZNF652
GENE_SYMBOLS	CETN2,CUL4B,DNAJC10,SKA2,RBM41,KCNK1,PABIR2,MPHOSPH9,PARD3,PTPN11,R3HDM1,RACGAP1,RPL10A,SH3GLB2,SMURF2,SSR3,SYNGR2,USH1C,ZBTB38,ZNF652
FOUNDER_NAMES